NO983632L - Krystallform av N-(4-trifluormetylfenyl)-5-metyl-isoksazol-4-karboksamid - Google Patents

Krystallform av N-(4-trifluormetylfenyl)-5-metyl-isoksazol-4-karboksamid

Info

Publication number: NO983632L
Authority: NO; Norway
Prior art keywords: trifluoromethylphenyl; isoxazole; carboxamide; methyl; crystal form
Prior art date: 1997-08-08

Application number

NO983632A

Other languages

English (en)

Other versions

NO983632D0 (no

NO310871B1 (no

Inventor

Holger Faasch

Udo Hedtmann

Uwe Westenfelder

Erich Paulus

Original Assignee

Hoechst Marion Roussel De Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-08-08

Filing date

1998-08-07

Publication date

1999-02-09

1997-08-08 Priority claimed from DE19734438A external-priority patent/DE19734438A1/de

1997-12-17 Priority claimed from DE1997156093 external-priority patent/DE19756093A1/de

1998-08-07 Application filed by Hoechst Marion Roussel De Gmbh filed Critical Hoechst Marion Roussel De Gmbh

1998-08-07 Publication of NO983632D0 publication Critical patent/NO983632D0/no

1999-02-09 Publication of NO983632L publication Critical patent/NO983632L/no

2001-09-10 Publication of NO310871B1 publication Critical patent/NO310871B1/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Immunology (AREA)
Pulmonology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Obesity (AREA)
Hematology (AREA)
Ophthalmology & Optometry (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Neurology (AREA)
Oncology (AREA)
Biomedical Technology (AREA)
Communicable Diseases (AREA)
Neurosurgery (AREA)
Reproductive Health (AREA)
Pain & Pain Management (AREA)
Orthopedic Medicine & Surgery (AREA)
Dermatology (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

NO19983632A 1997-08-08 1998-08-07 Krystallform av (N-(4-trifluormetylfenyl)-5-metyl-isoksazol-4- karboksamid), fremgangsmåte for fremstilling av denne, legemiddelinneholdende denne, samt anvendelse av krystallformen og enfremgangsmåte for fremstilling av modifikasjon 1 av forbi NO310871B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE19734438A DE19734438A1 (de)	1997-08-08	1997-08-08	Kristallform von N-(4-Trifluormethylphenyl)-5-methyl-isoxazole-4-carboxamid
DE1997156093 DE19756093A1 (de)	1997-12-17	1997-12-17	Verfahren zur Herstellung einer Kristallform von N-(4-Trifluormethylphenyl)-5-methyl-isoxazole-4-carboxamid

Publications (3)

Publication Number	Publication Date
NO983632D0 NO983632D0 (no)	1998-08-07
NO983632L true NO983632L (no)	1999-02-09
NO310871B1 NO310871B1 (no)	2001-09-10

Family

ID=26038983

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19983632A NO310871B1 (no)	1997-08-08	1998-08-07	Krystallform av (N-(4-trifluormetylfenyl)-5-metyl-isoksazol-4- karboksamid), fremgangsmåte for fremstilling av denne, legemiddelinneholdende denne, samt anvendelse av krystallformen og enfremgangsmåte for fremstilling av modifikasjon 1 av forbi

Country Status (28)

Country	Link
US (5)	US6060494A (no)
EP (2)	EP0903345B1 (no)
JP (2)	JPH11124372A (no)
KR (2)	KR100544041B1 (no)
CN (2)	CN1089759C (no)
AR (1)	AR015418A1 (no)
AT (2)	ATE207065T1 (no)
AU (1)	AU752764B2 (no)
BR (1)	BR9806568A (no)
CA (1)	CA2245267C (no)
CZ (3)	CZ292943B6 (no)
DE (2)	DE59801792D1 (no)
DK (2)	DK0903345T3 (no)
ES (2)	ES2166205T3 (no)
GR (1)	GR3034814T3 (no)
HK (2)	HK1017681A1 (no)
HU (2)	HU229232B1 (no)
ID (1)	ID20667A (no)
IL (1)	IL125671A (no)
NO (1)	NO310871B1 (no)
NZ (1)	NZ331270A (no)
PL (1)	PL192126B1 (no)
PT (2)	PT903345E (no)
RU (1)	RU2224753C2 (no)
SK (2)	SK285216B6 (no)
TR (2)	TR200600582A1 (no)
TW (1)	TW593288B (no)
UA (1)	UA54411C2 (no)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0903345B1 (de) *	1997-08-08	2000-10-04	Aventis Pharma Deutschland GmbH	Kristallform von 5-Methylisoxazol-4-carbonsäure-(4-trifluormethyl)-anilid
DE19908527C2 (de)	1999-02-26	2001-08-30	Aventis Pharma Gmbh	Verfahren zur Kristallisation von N-(4-Trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid
AU779931B2 (en) *	1999-12-16	2005-02-17	Teva Pharmaceutical Industries Ltd.	Novel processes for making- and a new crystalline form of- leflunomide
ES2237553T3 (es) *	2000-02-15	2005-08-01	Teva Pharmaceutical Industries Ltd.	Procedimiento para la sintesis de leflunomida.
WO2002040458A1 (fr) *	2000-11-17	2002-05-23	Takeda Chemical Industries, Ltd.	Derives d'isoxazole
GB0123571D0 (en)	2001-04-05	2001-11-21	Aventis Pharm Prod Inc	Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
US7429593B2 (en)	2001-09-14	2008-09-30	Shionogi & Co., Ltd.	Utilities of amide compounds
WO2003068239A1 (fr) *	2002-02-12	2003-08-21	Sumitomo Pharmaceuticals Co., Ltd.	Nouveaux medicaments d'usage externe
US20050158371A1 (en) *	2002-02-12	2005-07-21	Sumitomo Pharmaceuticals Co., Ltd.	Novel external agent
ES2232332T3 (es) *	2003-03-12	2007-08-16	Teva Pharmaceutical Industries Ltd	Composiciones farmaceuticas estables de desloratadina.
US20060135547A1 (en) *	2003-03-12	2006-06-22	Toth Zoltan G	Stable pharmaceutical compositions of desloratadine and processes for preparation of polymorphic forms of desloratadine
JP4223428B2 (ja) *	2004-03-31	2009-02-12	富士通メディアデバイス株式会社	フィルタおよびその製造方法
WO2007067710A1 (en) *	2005-12-08	2007-06-14	Amphora Discovery Corporation	Certain chemical entities, compositions, and methods for modulating trpv1
CN101143834B (zh) *	2006-09-15	2010-09-08	欣凯医药化工中间体（上海）有限公司	N-(4-三氟甲基苯)-2-氰基-3-羟基丁烯酰胺钠盐的多晶型及其制备方法
UY31695A (es) *	2008-03-10	2009-11-10	Takeda Pharmaceutical	Cristal de compuestos de bencimidazol
CN104666238B (zh)	2009-09-18	2018-04-06	赛诺菲	稳定性提高的(z)‑2‑氰基‑3‑羟基‑丁‑2‑烯酸‑(4’‑三氟甲基苯基)‑酰胺片剂制剂
CN103977594B (zh) *	2014-06-03	2016-02-17	江苏九九久科技股份有限公司	一种结晶方法
US9895370B2 (en) *	2015-11-19	2018-02-20	Pharmedix.Co., Ltd	Pharmaceutical composition for preventing or treating of cirrhosis of liver comprising G protein coupled receptor 119 ligand as an active ingredient
CN109180599A (zh) *	2018-09-03	2019-01-11	深圳市新阳唯康科技有限公司	一种来氟米特新晶型化合物及其制备方法
CN112898215B (zh) *	2021-02-04	2022-11-08	美罗药业股份有限公司	一种来氟米特晶型i的制备方法
CN114716388B (zh) *	2021-11-04	2024-02-13	江苏冠军科技集团股份有限公司	一种磺胺-银化合物及其制备方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2524959C2 (de) *	1975-06-05	1983-02-10	Hoechst Ag, 6000 Frankfurt	5-Methyl-isoxazol-4-carbonsäureanilide, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Mittel
NL186239B (nl) *	1975-06-05		Hoechst Ag	Werkwijze voor de bereiding van een geneesmiddel met antiflogistische en/of analgetische werking, alsmede werkwijze voor de bereiding van een 2-hydroxyethylideencyaanazijnzuuranilide geschikt voor toepassing bij deze werkwijze.
ES448386A1 (es) *	1975-06-05	1978-04-16	Hoechst Ag	Procedimiento para la preparacion de anilidas de acido 5-me-til-isoxazol-4-carboxilico.
DE2525959A1 (de) *	1975-06-11	1977-02-10	Focke Pfuhl Verpack Automat	Verpackung fuer zigaretten, zigarillos etc.
DE2854439A1 (de) *	1978-12-16	1980-07-03	Hoechst Ag	Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung
IL63968A (en) *	1980-10-01	1985-10-31	Glaxo Group Ltd	Form 2 ranitidine hydrochloride,its preparation and pharmaceutical compositions containing it
US4935434A (en) *	1988-01-26	1990-06-19	Bristol-Myers Company	Antiarthritic isoxazole-4-carboxamides
US5583150A (en) *	1989-08-18	1996-12-10	Alcon Laboratories, Inc.	5-methyl-isoxazole-4-carboxylic acid anilides and 2-hydroxyethylidene-cyano acetic anilides for the treatment of ocular diseases
DK0527736T3 (da) *	1990-05-18	1997-10-20	Hoechst Ag	Isoxazol-4-carboxylsyreamider og hydroxyalkyliden-cyanoacetamider, lægemidler indeholdende disse forbindelser og anvendelsen af disse lægemidler.
DE4127737A1 (de) *	1991-08-22	1993-02-25	Hoechst Ag	Arzneimittel zur behandlung von abstossungsreaktionen bei organverpflanzungen
GB9209330D0 (en) *	1992-04-30	1992-06-17	Roussel Lab Ltd	Chemical compounds
ES2124800T3 (es) *	1993-01-08	1999-02-16	Hoechst Ag	Empleo de leflunomida para la inhibicion de interleuquina 1 beta.
ATE174219T1 (de) *	1993-01-08	1998-12-15	Hoechst Ag	Verwendung von leflunomid zur hemmung von tumornekrosefaktor alpha
ATE174220T1 (de) *	1993-01-08	1998-12-15	Hoechst Ag	Verwendung von leflunomid zur hemmung von interleukin 8
TW314467B (no) *	1993-03-31	1997-09-01	Hoechst Ag
GB9320299D0 (en) *	1993-10-01	1993-11-17	Roussel Lab Ltd	Isoxazole derivatives
US5610173A (en) *	1994-01-07	1997-03-11	Sugen, Inc.	Formulations for lipophilic compounds
ATE194912T1 (de) *	1994-10-17	2000-08-15	Aventis Pharma Ltd	Mittel zur vorsorge und heilung von typ i allergischen krankheiten
AR001982A1 (es) *	1995-02-06	1998-01-07	Smithkline Beecham Plc	Clorhidrato de paroxetina anhidratado, y procedimiento para su preparacion
DE19539638A1 (de) *	1995-10-25	1997-04-30	Hoechst Ag	Die Verwendung von Isoxazol- und Crotonsäureamidderivaten zur Behandlung von Krebserkrankungen
US6316479B1 (en) *	1997-05-19	2001-11-13	Sugen, Inc.	Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders
HRP980291A2 (en) *	1997-06-16	1999-04-30	Lin-Hua Zhang	Crystalline roxifiban
EP0903345B1 (de) *	1997-08-08	2000-10-04	Aventis Pharma Deutschland GmbH	Kristallform von 5-Methylisoxazol-4-carbonsäure-(4-trifluormethyl)-anilid
US6096770A (en) *	1998-08-03	2000-08-01	American Home Products Corporation	Anthranilic acid analogs
DE19908527C2 (de) *	1999-02-26	2001-08-30	Aventis Pharma Gmbh	Verfahren zur Kristallisation von N-(4-Trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid
AU779931B2 (en) *	1999-12-16	2005-02-17	Teva Pharmaceutical Industries Ltd.	Novel processes for making- and a new crystalline form of- leflunomide
ES2237553T3 (es) *	2000-02-15	2005-08-01	Teva Pharmaceutical Industries Ltd.	Procedimiento para la sintesis de leflunomida.
US6727272B1 (en) *	2002-07-15	2004-04-27	Unitech Pharmaceuticals, Inc.	Leflunomide analogs for treating rheumatoid arthritis

1998
- 1998-07-31 EP EP98114373A patent/EP0903345B1/de not_active Expired - Lifetime
- 1998-07-31 AT AT99117098T patent/ATE207065T1/de active
- 1998-07-31 PT PT98114373T patent/PT903345E/pt unknown
- 1998-07-31 ES ES99117098T patent/ES2166205T3/es not_active Expired - Lifetime
- 1998-07-31 DK DK98114373T patent/DK0903345T3/da active
- 1998-07-31 DE DE59801792T patent/DE59801792D1/de not_active Expired - Lifetime
- 1998-07-31 PT PT99117098T patent/PT987256E/pt unknown
- 1998-07-31 ES ES98114373T patent/ES2150808T3/es not_active Expired - Lifetime
- 1998-07-31 EP EP99117098A patent/EP0987256B1/de not_active Expired - Lifetime
- 1998-07-31 DE DE59800287T patent/DE59800287D1/de not_active Expired - Lifetime
- 1998-07-31 AT AT98114373T patent/ATE196764T1/de active
- 1998-07-31 DK DK99117098T patent/DK0987256T3/da active
- 1998-08-05 CZ CZ19982468A patent/CZ292943B6/cs not_active IP Right Cessation
- 1998-08-05 IL IL12567198A patent/IL125671A/en not_active IP Right Cessation
- 1998-08-05 CZ CZ20032982A patent/CZ301514B6/cs not_active IP Right Cessation
- 1998-08-05 CZ CZ20032983A patent/CZ301426B6/cs not_active IP Right Cessation
- 1998-08-06 UA UA98084307A patent/UA54411C2/uk unknown
- 1998-08-06 TW TW087112927A patent/TW593288B/zh not_active IP Right Cessation
- 1998-08-06 US US09/129,783 patent/US6060494A/en not_active Expired - Lifetime
- 1998-08-06 AR ARP980103900A patent/AR015418A1/es active IP Right Grant
- 1998-08-06 NZ NZ331270A patent/NZ331270A/xx not_active IP Right Cessation
- 1998-08-06 TR TR2006/00582A patent/TR200600582A1/xx unknown
- 1998-08-06 SK SK1521-2001A patent/SK285216B6/sk not_active IP Right Cessation
- 1998-08-06 SK SK1058-98A patent/SK282641B6/sk not_active IP Right Cessation
- 1998-08-06 TR TR1998/01513A patent/TR199801513A3/tr unknown
- 1998-08-06 ID IDP981098A patent/ID20667A/id unknown
- 1998-08-07 JP JP10224015A patent/JPH11124372A/ja active Pending
- 1998-08-07 HU HU0700190A patent/HU229232B1/hu unknown
- 1998-08-07 CA CA002245267A patent/CA2245267C/en not_active Expired - Lifetime
- 1998-08-07 AU AU78870/98A patent/AU752764B2/en not_active Expired
- 1998-08-07 BR BR9806568-8A patent/BR9806568A/pt not_active Application Discontinuation
- 1998-08-07 CN CN98116235A patent/CN1089759C/zh not_active Expired - Lifetime
- 1998-08-07 KR KR1019980032110A patent/KR100544041B1/ko not_active IP Right Cessation
- 1998-08-07 HU HU9801844A patent/HU225870B1/hu unknown
- 1998-08-07 RU RU98115390/04A patent/RU2224753C2/ru active
- 1998-08-07 CN CNB021045747A patent/CN1181064C/zh not_active Expired - Lifetime
- 1998-08-07 NO NO19983632A patent/NO310871B1/no not_active IP Right Cessation
- 1998-08-07 PL PL327901A patent/PL192126B1/pl unknown
1999
- 1999-06-30 HK HK99102767A patent/HK1017681A1/xx not_active IP Right Cessation
- 1999-10-28 US US09/428,499 patent/US6221891B1/en not_active Expired - Lifetime
2000
- 2000-11-10 GR GR20000402501T patent/GR3034814T3/el unknown
2001
- 2001-01-19 US US09/764,258 patent/US6552202B2/en not_active Expired - Lifetime
2002
- 2002-11-25 US US10/302,872 patent/US6900334B2/en not_active Expired - Lifetime
2003
- 2003-02-19 HK HK03101247.6A patent/HK1049481B/zh not_active IP Right Cessation
2004
- 2004-04-23 US US10/830,307 patent/US6995272B2/en not_active Expired - Lifetime
2005
- 2005-06-28 KR KR1020050056044A patent/KR100588254B1/ko not_active IP Right Cessation
2009
- 2009-07-28 JP JP2009175137A patent/JP2009280604A/ja active Pending

Also Published As

Publication number	Publication date
HK1049481B (zh)	2005-07-08
UA54411C2 (uk)	2003-03-17
SK105898A3 (en)	1999-02-11
HUP9801844A2 (hu)	2000-02-28
HU225870B1 (en)	2007-11-28
CA2245267C (en)	2008-12-23
TW593288B (en)	2004-06-21
CZ301514B6 (cs)	2010-03-31
DE59801792D1 (de)	2001-11-22
PL327901A1 (en)	1999-02-15
HU229232B1 (en)	2013-09-30
US6552202B2 (en)	2003-04-22
CN1373126A (zh)	2002-10-09
JP2009280604A (ja)	2009-12-03
TR199801513A2 (xx)	1999-02-22
US6221891B1 (en)	2001-04-24
JPH11124372A (ja)	1999-05-11
US6060494A (en)	2000-05-09
CN1089759C (zh)	2002-08-28
TR199801513A3 (tr)	1999-02-22
US6900334B2 (en)	2005-05-31
CZ301426B6 (cs)	2010-02-24
IL125671A (en)	2002-11-10
US20030166945A1 (en)	2003-09-04
KR100588254B1 (ko)	2006-06-12
CN1208034A (zh)	1999-02-17
CA2245267A1 (en)	1999-02-08
ES2166205T3 (es)	2002-04-01
US20030027851A1 (en)	2003-02-06
CN1181064C (zh)	2004-12-22
ID20667A (id)	1999-02-11
EP0987256A1 (de)	2000-03-22
DE59800287D1 (de)	2000-11-09
CZ292943B6 (cs)	2004-01-14
HK1017681A1 (en)	1999-11-26
IL125671A0 (en)	1999-04-11
AU7887098A (en)	1999-02-18
PT987256E (pt)	2002-03-28
ATE196764T1 (de)	2000-10-15
DK0903345T3 (da)	2000-10-23
PL192126B1 (pl)	2006-09-29
BR9806568A (pt)	2000-05-16
NO983632D0 (no)	1998-08-07
US6995272B2 (en)	2006-02-07
RU2224753C2 (ru)	2004-02-27
KR20050077498A (ko)	2005-08-02
HU9801844D0 (en)	1998-10-28
CZ246898A3 (cs)	1999-02-17
AU752764B2 (en)	2002-09-26
SK285216B6 (sk)	2006-09-07
TR200600582A1 (tr)	2006-08-21
ES2150808T3 (es)	2000-12-01
EP0903345A1 (de)	1999-03-24
DK0987256T3 (da)	2002-02-11
AR015418A1 (es)	2001-05-02
NO310871B1 (no)	2001-09-10
EP0903345B1 (de)	2000-10-04
PT903345E (pt)	2001-01-31
HU0700190D0 (en)	2007-05-02
HK1049481A1 (en)	2003-05-16
GR3034814T3 (en)	2001-02-28
HUP9801844A3 (en)	2000-04-28
KR100544041B1 (ko)	2006-09-18
EP0987256B1 (de)	2001-10-17
ATE207065T1 (de)	2001-11-15
NZ331270A (en)	2000-04-28
US20040204465A1 (en)	2004-10-14
KR19990023433A (ko)	1999-03-25
SK282641B6 (sk)	2002-10-08

Publication	Publication Date	Title
NO983632L (no)	1999-02-09	Krystallform av N-(4-trifluormetylfenyl)-5-metyl-isoksazol-4-karboksamid
NO331016B1 (no)	2011-09-12	Krystallmodifikasjon av et N-fenyl-2-pyrimidinaminderivat
FI962932A (fi)	1996-09-20	Ankkuriproteiinifunktion modulaattoreita
NL300284I2 (nl)	2007-11-01	Kristalmodificatie van
DK1445259T3 (da)	2006-10-16	Anvendelse af krystalformer for 2-methyl-thieno-benzodiazepin
DE69928195D1 (de)	2005-12-15	Komplettierung von Untrerdruck-Bohrlöchern
ID29306A (id)	2001-08-16	Bentuk baru s-omeprazola
FI973596A0 (fi)	1997-09-04	Identifikation av talaktiviteten av en kaella
ID24458A (id)	2000-07-20	Modifikasi rheologi in-sito poliolefin
ID21725A (id)	1999-07-15	Kompresor jenis piringan hentak
ATE243197T1 (de)	2003-07-15	Kristallformen von osanetant
CY2005003I2 (el)	2011-02-02	Mεθοδοι και ενδιαμεσα χρησιμα για κατασκευη αντιφολικων
DE69823908D1 (de)	2004-06-24	Einkristallziehvorrichtung
DE69502429D1 (de)	1998-06-18	Auflösung von Gas
ATE232199T1 (de)	2003-02-15	Polymorphe modifikationen von dofetilid
FI974508A (fi)	1999-06-13	Iskuja synnyttävä laite
SI0987256T1 (en)	2002-04-30	Crystal form of N-(4-trifluoromethylphenyl)-5-methylisoxazole-4-carboxamid
DE59802280D1 (de)	2002-01-17	Herstellung von Oxazolderivaten
IL139438A0 (en)	2001-11-25	Crystal form of n- (4-trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide
ZA987127B (en)	1999-02-08	Crystal form of N-(4-trifuloromethylphenyl)-5-methylisoxazole-4-carboxamide
NO980913D0 (no)	1998-03-03	Alternativ krystallform av tazofelon
KR970011853U (ko)	1997-04-25	새로운 형태의 메리야스
SE9600037D0 (sv)	1996-01-05	Modifiering av cement
UA644S (uk)	1994-12-29	Мікро-еом широкого призначення
SE9400957D0 (sv)	1994-03-23	Kantelement av betong

Legal Events

Date	Code	Title	Description
2018-09-10	MK1K	Patent expired